Deepinder Goyal’s brain-wearable startup Temple has acquired Longevous, pulling the cofounders into full-time roles steering the science.
It started, as these things sometimes do, with someone noticing a strange gadget at a dinner party. Deepinder Goyal, the entrepreneur behind Zomato, now running a health-tech startup called Temple, says he first met Dr Robert Mohr and Dr Avi Roy at a dinner in London a few months back, after the two noticed a device strapped to his temple and asked what on earth it was.
That conversation has now turned into an acquisition. Temple has bought Longevous, the London-based longevity care company Mohr and Roy founded, and both men are joining Temple full-time – Mohr as chief medical officer, Roy as head of science. Goyal announced the deal on X: “Temple acquires London-based Longevous.”
The device that started it all
Temple is Goyal’s bet on a fairly specific corner of health tech: a wearable designed to experimentally monitor cerebral blood flow (circulation in the brain) in real time, with an eye toward brain and cognitive health. It’s an unusual thing to build a company around, and an unusual thing to wear to dinner, which is presumably why it caught two longevity specialists’ attention in the first place.
According to Goyal, Mohr and Roy didn’t just ask polite questions and move on. They tried the device themselves, wearing it for two months to track their own data, then started working directly with Temple’s science team to pressure-test the technology.
“They challenged our assumptions and poked holes in our vision,” Goyal told Business Today, adding that the pair became involved in Temple’s validation work and reviewed its first scientific manuscripts before submission – an informal audition, in hindsight, for the roles they’ve now been handed formally [1].
Two scientists, two very different resumes
Mohr and Roy bring distinct backgrounds to the new arrangement. Mohr is a board-certified physician with close to two decades of clinical experience, who moved from emergency medicine into evidence-based longevity medicine, with a focus on preventive and precision care, exactly the clinical grounding a company making real-time health claims about its hardware needs on staff.
Meanwhile, Roy is an Oxford-trained biomedical scientist who has worked at the intersection of longevity science and business, co-founding Founders Health and UDA, and previously serving as a research fellow at Oxford’s Centre for the Advancement of Sustainable Medical Innovation.
Under the new structure, Longevous keeps operating as part of Temple, with Mohr and Roy continuing to personally oversee its existing clients. Their day jobs, though, will shift toward Temple itself: Mohr bringing clinical rigor to the company’s experiments and public claims, Roy leading the science function more broadly.
It’s a slightly unusual direction of travel. Plenty of longevity clinics have looked to acquire wearable or diagnostic technology to bolt onto their client offering; here, it’s the hardware company absorbing the clinical outfit, and with it, two specialists whose entire professional identity is built around longevity medicine rather than consumer tech. It suggests Temple sees clinical credibility, not just a novel sensor, as the thing it was actually short on.
Strip away the wearable-tech framing and what’s happening is a straightforward consolidation inside the longevity industry itself: a company built around monitoring brain and cognitive health absorbing a clinical practice built around evidence-based longevity care, then installing that practice’s founders as the people responsible for making sure the science holds up.
As more consumer health hardware companies chase legitimacy in the aging space, expect more of this pattern: technology firms buying clinical expertise rather than trying to grow it in-house.
